THRD Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Third Harmonic Bio's net margin of 21.68%. Third Harmonic Bio's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Third Harmonic Bio has a consensus price target of $4.58, signalling downside risk potential of -11.31%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 29.55%. Given that Eli Lilly and has higher upside potential than Third Harmonic Bio, analysts believe Eli Lilly and is more attractive than Third Harmonic Bio.

Third Harmonic Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Third Harmonic Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Third Harmonic Bio pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Third Harmonic Bio quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Third Harmonic Bio's net income of -$15.8M is lower than Eli Lilly and's net income of $2.8B. Notably, Third Harmonic Bio's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 61.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Third Harmonic Bio is -- versus 13.93x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Third Harmonic Bio's net margin of -49.65%. Third Harmonic Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Third Harmonic Bio has a consensus price target of $4.58, signalling downside risk potential of -11.31%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 54.52%. Given that NovaBay Pharmaceuticals has higher upside potential than Third Harmonic Bio, analysts believe NovaBay Pharmaceuticals is more attractive than Third Harmonic Bio.

Third Harmonic Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Third Harmonic Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Third Harmonic Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Third Harmonic Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Third Harmonic Bio's net income of -$15.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Third Harmonic Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Third Harmonic Bio is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Internet Patents Corporation has a net margin of -- compared to Third Harmonic Bio's net margin of --. Third Harmonic Bio's return on equity of -- beat Internet Patents Corporation's return on equity of --.

Third Harmonic Bio has a consensus price target of $4.58, signalling downside risk potential of -11.31%. On the other hand Internet Patents Corporation has an analysts' consensus of -- which suggests that it could fall by --. Given that Third Harmonic Bio has higher upside potential than Internet Patents Corporation, analysts believe Third Harmonic Bio is more attractive than Internet Patents Corporation.

Third Harmonic Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Internet Patents Corporation has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Third Harmonic Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Internet Patents Corporation offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Third Harmonic Bio pays -- of its earnings as a dividend. Internet Patents Corporation pays out -- of its earnings as a dividend.

Third Harmonic Bio quarterly revenues are --, which are smaller than Internet Patents Corporation quarterly revenues of --. Third Harmonic Bio's net income of -$15.8M is higher than Internet Patents Corporation's net income of --. Notably, Third Harmonic Bio's price-to-earnings ratio is -- while Internet Patents Corporation's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Third Harmonic Bio is -- versus -- for Internet Patents Corporation. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Third Harmonic Bio's net margin of --. Third Harmonic Bio's return on equity of -- beat Theriva Biologics's return on equity of --.

Third Harmonic Bio has a consensus price target of $4.58, signalling downside risk potential of -11.31%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1252.66%. Given that Theriva Biologics has higher upside potential than Third Harmonic Bio, analysts believe Theriva Biologics is more attractive than Third Harmonic Bio.

Third Harmonic Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Third Harmonic Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Third Harmonic Bio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Third Harmonic Bio quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Third Harmonic Bio's net income of -$15.8M is lower than Theriva Biologics's net income of -$4.4M. Notably, Third Harmonic Bio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Third Harmonic Bio is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.